CMS Presented its Innovative Drug ILUMETRI at the 2023 Frontier Conference on New Developments of Dermatological Treatment

Company News

On November 25, 2023, the “Innovative Medicine Brings Brighter Future of Skin Health – 2023 Frontiers Conference on New Developments of Dermatological Treatment” was grandly held in Sanya, Hainan Province. The conference was co-organized by Hainan Lecheng Real World Research Institute and Hainan Boao Lecheng International Medical Tourism Pioneer Zone Administration. It brought together many top domestic scholars and clinical experts in the dermatology field to share in-depth research on the pathogenesis, diagnosis and treatment of psoriasis and vitiligo, providing more new technologies and therapies for the clinical treatment of the related diseases.


The innovative drug for psoriasis treatment, ILUMETRI (Tildrakizumab Injection) made its debut at the conference, demonstrating CMS’s ability to empower the continuous transformation of innovative outcomes into diagnosis and therapeutic practice.



Gathering leading academic forces

Exchanging new developments in dermatological treatment


More than 200 medical experts in the field of psoriasis and vitiligo treatment from across the country attended the conference to conduct in-depth discussions on topical and difficult issues in dermatology treatment, aiming to bring more insights into the treatment of skin diseases in China by linking the strengths of all parties. At the same time, the conference focused on the new journey of psoriasis treatment, interpreted the new development prospects of IL-23 inhibitors in skin treatment, discussed the future of innovative immunotherapy, to build a new development pattern in the field of dermatology treatment.


CMS is dedicated to the mission of providing competitive products and services to meet unmet medical needs. This time, CMS brought its innovative drug ILUMETRI (Tildrakizumab Injection) to the conference, ILUMETRI is expected to provide a better choice for the long-term treatment and disease management of psoriasis patients in China.


Mr. Huang Anjun, General Manager of CMS’s Dermatology and Medical Aesthetic Business, said, “We are very pleased to present our innovative outcomes on this cutting-edge conference. CMS will accelerate the commercialization process of ILUMETRI and promote subsequent academic promotion work to achieve large-scale clinical application, providing adult patients suffering moderate to severe plaque psoriasis in China with a better long-term treatment option that is safe and effective.”


The large-scale clinical application of psoriasis treatment new drugs has officially begun

Tens of millions of psoriasis patients gain new treatment options


Psoriasis is an autoimmune disease with complex causes, and IL-23 is considered to be one of the important inducing factors in the pathogenesis of psoriasis. The incidence rate of psoriasis in China is about 0.47%, with the number of patients exceeding 7 million, of whom more than half have developed into moderate to severe disease.


On May 26, 2023, CMS’s innovative drug ILUMETRI (Tildrakizumab Injection) was approved for marketing by the China National Medical Products Administration (NMPA) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.


ILUMETRI is a humanized lgG1/κ monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor. Thereby leading to inhibition of the release of pro-inflammatory cytokines and chemokines. The extended study of ILUMETRI’s Phase III clinical trial in China, demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3% at week 52, and ILUMETRI showed good long-term safety and tolerance. The maintenance period of ILUMETRI requires only 4 administrations per year, which may lead to higher patient compliance.


Innovation development is a long and arduous task

Joining forces to support the construction of “Healthy China”


In-depth exchanges and discussions among participating dermatology experts at this conference are expected to raise more exploration in new diagnosis and treatment therapies, and more multi-disciplinary and multi-dimensional cooperation, bringing unlimited possibilities for drug innovation and development and clinical application expansion to jointly construct “healthy China”.


Based on its own commercialization capabilities and clinical resources with scale effect, CMS has cooperated extensively with global innovation forces to jointly develop innovative pharmaceutical products with academic value and differentiated advantages to improve the accessibility of global innovative drugs to Chinese patients. After over five years of R&D investment and advancement, in 2023, in addition to Tildrakizumab Solution for Injection (ILUMETRI), CMS also successfully obtained China marketing approvals for Methotrexate Injection (METOJECT, the first Methotrexate pre-filled injection for subcutaneous administration for the treatment of psoriasis in China) and China’s first Diazepam Nasal Spray (VALTOCO, an innovative medicine targeting acute repetitive seizures that is convenient to use with a very rapid onset of action). In addition, more than ten innovative drugs are under clinical trials stages (mainly RCTs). CMS will continuously provide patients with more new and effective drugs.


The exploration of innovative drugs is a long and arduous process. CMS focuses on urgent unmet clinical needs, continuously increases investment in innovation, enhances research capabilities, and promotes clinical development and marketing registration of more innovative products , benefiting more patients and contributing to the “Healthy China” strategy and people’s better life with CMS power.